The aim of this study was to improve the oral bioavailability of buprenorphine by inhibiting presystemic metabolism via the oral co‐administration of ‘Generally Recognized as Safe’ compounds, thus providing an… Click to show full abstract
The aim of this study was to improve the oral bioavailability of buprenorphine by inhibiting presystemic metabolism via the oral co‐administration of ‘Generally Recognized as Safe’ compounds, thus providing an orally administered drug product with less variability and comparable or higher exposure compared with the sublingual route.
               
Click one of the above tabs to view related content.